DK1222929T3 - Fremgangsmåde og farmaceutisk sammensætning til forebyggelse og/eller behandling af systematisk betændelsesreaktionssyndrom - Google Patents

Fremgangsmåde og farmaceutisk sammensætning til forebyggelse og/eller behandling af systematisk betændelsesreaktionssyndrom

Info

Publication number
DK1222929T3
DK1222929T3 DK02447005.6T DK02447005T DK1222929T3 DK 1222929 T3 DK1222929 T3 DK 1222929T3 DK 02447005 T DK02447005 T DK 02447005T DK 1222929 T3 DK1222929 T3 DK 1222929T3
Authority
DK
Denmark
Prior art keywords
systemic inflammatory
prevention
treatment
pharmaceutical composition
inflammatory reaction
Prior art date
Application number
DK02447005.6T
Other languages
English (en)
Inventor
Marc G Jacquemin
Jean-Marie R Saint-Remy
Original Assignee
Life Sciences Res Partners Vzw
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Life Sciences Res Partners Vzw filed Critical Life Sciences Res Partners Vzw
Application granted granted Critical
Publication of DK1222929T3 publication Critical patent/DK1222929T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK02447005.6T 2001-01-11 2002-01-11 Fremgangsmåde og farmaceutisk sammensætning til forebyggelse og/eller behandling af systematisk betændelsesreaktionssyndrom DK1222929T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26140501P 2001-01-11 2001-01-11

Publications (1)

Publication Number Publication Date
DK1222929T3 true DK1222929T3 (da) 2010-09-06

Family

ID=22993164

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02447005.6T DK1222929T3 (da) 2001-01-11 2002-01-11 Fremgangsmåde og farmaceutisk sammensætning til forebyggelse og/eller behandling af systematisk betændelsesreaktionssyndrom

Country Status (7)

Country Link
EP (1) EP1222929B8 (da)
AT (1) ATE468136T1 (da)
CY (1) CY1110781T1 (da)
DE (1) DE60236386D1 (da)
DK (1) DK1222929T3 (da)
ES (1) ES2346189T3 (da)
PT (1) PT1222929E (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829085B2 (en) 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
TW200407335A (en) 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
WO2004065418A1 (ja) * 2003-01-20 2004-08-05 Chugai Seiyaku Kabushiki Kaisha 抗pci中和抗体
US7785594B2 (en) 2003-08-14 2010-08-31 Life Sciences Research Partners Vzw Factor VIII inhibitory antibodies with reduced glycosylation
US8119137B2 (en) * 2004-12-23 2012-02-21 Csl Behring Gmbh Prevention of thrombus formation and/or stabilization with inhibitors of factor XII or activated factor XII
JP2009502149A (ja) 2005-07-29 2009-01-29 ライフ・サイエンシーズ・リサーチ・パートナーズ・フェレニゲング・ゾンデル・ウィンストーメルク 新規な抗第ｖｉｉｉ因子抗体
CN102234641A (zh) * 2010-05-05 2011-11-09 杭州星博生物科技有限公司 一种快速获取特异性人源抗体可变区基因序列的方法
DE102013005184A1 (de) * 2013-03-20 2014-09-25 fzmb GmbH, Forschungszentrum für Medizintechnik und Biotechnologie Verfahren zur Funktionalisierung einer Oberfläche

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
ES2283308T3 (es) * 1999-07-14 2007-11-01 D. Collen Research Foundation Vzw Anticuerpo monoclonal para el factor viii, que incluso cuando esta presente en exceso molar inactiva el factor viii solo en parte y metodo para producir dicho anticuerpo.

Also Published As

Publication number Publication date
EP1222929A2 (en) 2002-07-17
CY1110781T1 (el) 2015-06-10
ES2346189T3 (es) 2010-10-13
PT1222929E (pt) 2010-08-18
EP1222929A3 (en) 2002-09-18
ATE468136T1 (de) 2010-06-15
EP1222929B8 (en) 2010-07-07
DE60236386D1 (de) 2010-07-01
EP1222929B1 (en) 2010-05-19

Similar Documents

Publication Publication Date Title
CY1110781T1 (el) Μεθοδος και φαρμακευτικη συνθεση για την προληψη και/ή την θεραπευτικη αγωγη του συνδρομου συστημικης φλεγμονωδους αποκρισης
DK1325033T3 (da) Inhibering af komplement C5 aktivering til behandlingen og forebyggelsen af forsinket xenograf- eller akut vaskulær afstødning
NO20031471L (no) Glykoformer av faktor VII
DK1569899T3 (da) Substituerede 3-alkyl- og 3-arylalkyl-1H-indol-1-yl-eddikesyrederivater som inhibitorer af plasminogenaktivator-inhibitor-1 (PAI-1)
NO20031500L (no) Brodekkepaneler, fremgangsmåte for fremstilling av samme og broer omfattende samme
ATE339425T1 (de) Platelet adp rezeptor inhibitoren
DK1257550T3 (da) Blodplade-ADP-receptor-inhibitor
CO5580797A2 (es) Anticuerpos anti-cd33 y metodo para tratamiento de leucemia mieloide aguda utilizando los mismos
ATE360417T1 (de) Methode zur behandlung von zytokinvermittelten erkrankungen
EA200501805A1 (ru) Фармацевтическая композиция, содержащая ингибитор фермента дипептидилпептидазы
DK1362052T3 (da) Inhibitorer af cruzipain og andre cysteinproteaser
DE60315323D1 (de) Piperidinderivate zur verwendung bei der behandlung von durch chemokins vermittelten leiden
EA200301248A1 (ru) Применение ингибиторов il-18 для лечения или предупреждения сепсиса
MA25847A1 (fr) Composition pour le traitement du dysfonctionnement endothelial.
DK0587799T3 (da) Inhibitorer af cathepsin G og elastase til forebyggelse af bindevævsnedbrydning
EA200300027A1 (ru) Способ лечения сердечно-сосудистых заболеваний
EA200400410A1 (ru) Комбинация нспвлс и ингибитора pde-4
ATE355067T1 (de) 15-keto-prostaglandine zur behandlung arzneimittelinduzierter obstipation
ATE332145T1 (de) Arzneien zur begleitenden behandlung von glaukomen
NL1019899A1 (nl) Verwijdering van onzuiverheden uit koolwaterstofstromen.
EP1343809A4 (en) PROCESS FOR PREPARING AN ALPHA-1 PROTEINASE INHIBITOR
WO2003093242A3 (en) Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
HK1051319A1 (zh) 治疗感染疾病的方法和组合物
DE69226432D1 (de) 2-spirocyclopropyl 4-acylcephalosporine und verfahren zu ihrer herstellung
DE60135665D1 (de) Neue amidino-derivate und deren verwendung als thrombin-inhibitoren